scholarly journals Antigen recognition. V. Requirement for histocompatibility between antigen-presenting cell and B cell in the response to a thymus-dependent antigen, and lack of allogeneic restriction between T and B cells.

1981 ◽  
Vol 154 (3) ◽  
pp. 676-687 ◽  
Author(s):  
E Nisbet-Brown ◽  
B Singh ◽  
E Diener
Keyword(s):  
B Cells ◽  
B Cell ◽  
Cell Function ◽  
Fetal Liver ◽  
T And B Cells ◽  
Antigen Presenting Cell ◽  
Experimental Conditions ◽  
Left Hand ◽  
Antigen Presenting

The restrictions imposed by the major histocompatibility complex on T-B-antigen-presenting cell (APC) interactions were studied with an in vivo adoptive transfer system, using mutually tolerant T and B cells taken from one-way fetal liver chimeras. It was found that the B cells and adoptive recipient (which provides APC function) have to share determinants encoded by the left-hand end of the H-2 complex for cooperation, whereas there is apparently no such requirement for T-B cell syngeneicity. Suppression arising from allogeneic effects between the host and the transferred T or B cells was excluded by the use of tolerant as well as normal adoptive recipients; both were functionally equivalent. We conclude that under experimental conditions, unrestricted helper T cell function and concurrent APC-B cell genetic restriction can be demonstrated in vivo.

scholarly journals The fate of fetal and adult B-cell progenitors grafted into immunodeficient CBA/N mice.

1979 ◽  
Vol 150 (3) ◽  
pp. 548-563 ◽  
Author(s):  
C J Paige ◽  
P W Kincade ◽  
M A Moore ◽  
G Lee
Keyword(s):  
B Cells ◽  
B Cell ◽  
Fetal Liver ◽  
Cell Cloning ◽  
Generate Functional ◽  
Self Renewal ◽  
Relative Ability ◽  
Cloning Assay ◽  
Regenerative Ability

The relative ability of various precursors to generate functional B cells in vivo was assessed by transferring normal, chromosomally-marked CBA/H-T6T6 cells to irradiated or unirradiated immunodeficient CBA/N mice. Emergence of donor-derived B cells was monitored by means of a B-cell cloning assay (in which CBA/N cells are inactive), and by karyotpic analysis of lymphoid, myeloid, and stem cell metaphases. Grafts of lymph node, spleen, anti-mu surface immunoglobin suppressed bone marrow, sIg+ cell-depleted marrow, normal marrow, fetal liver, and yolk sac suggest: (a) there is little self-renewal of sIg+ B cells in these models; (b) pre-committed cells have extensive proliferative/differentiative potential and at least initially contribute most of the newly-formed B cells; (c) populations or pre-B cells obtained from various sources differ in their regenerative ability; (d) CBA/N mice are deficient in a category of pre-B cells which are found in fetal liver; and (e) selective B-cell chimerism results from grafting of unirradiated CBA/N mice.

scholarly journals Engagement of CD83 on B Cells Modulates B Cell Function In Vivo

2009 ◽  
Vol 182 (5) ◽  
pp. 2827-2834 ◽  
Author(s):  
Birte Kretschmer ◽  
Katja Lüthje ◽  
Stefanie Schneider ◽  
Bernhard Fleischer ◽  
Minka Breloer
Keyword(s):  
B Cells ◽  
B Cell ◽  
Cell Function ◽  
B Cell Function

Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo

10.1038/nm962 ◽  
2003 ◽  
Vol 9 (12) ◽  
pp. 1469-1476 ◽  
Author(s):  
Douglas G Millar ◽  
Kristine M Garza ◽  
Bernhard Odermatt ◽  
Alisha R Elford ◽  
Nobuyuki Ono ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Function ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Antigen Presenting Cell ◽  
Antigen Presenting

Enhancement of B Cell Function as Antigen-Presenting Cell during Interplay with Th Cells

Immunobiology ◽  
1994 ◽  
Vol 190 (4-5) ◽  
pp. 317-332
Author(s):  
Kazuhiko Nakamachi ◽  
Kazuo Nagai ◽  
Hideo Nariuchi ◽  
Terutaka Kakiuchi
Keyword(s):  
B Cell ◽  
Cell Function ◽  
Antigen Presenting Cell ◽  
Th Cells ◽  
B Cell Function ◽  
Antigen Presenting

scholarly journals LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1

Blood ◽  
2008 ◽  
Vol 111 (3) ◽  
pp. 1448-1455 ◽  
Author(s):  
Julia Rastelli ◽  
Cornelia Hömig-Hölzel ◽  
Jane Seagal ◽  
Werner Müller ◽  
Andrea C. Hermann ◽  
...  
Keyword(s):  
B Cells ◽  
B Cell ◽  
Cell Function ◽  
Somatic Hypermutation ◽  
Class Switch Recombination ◽  
Cd40 Ligand ◽  
Barr Virus ◽  
Class Switch ◽  
Epstein Barr

AbstractThe Epstein-Barr virus (EBV) protein LMP1 is considered to be a functional homologue of the CD40 receptor. However, in contrast to the latter, LMP1 is a constitutively active signaling molecule. To compare B cell–specific LMP1 and CD40 signaling in an unambiguous manner, we generated transgenic mice conditionally expressing a CD40/LMP1 fusion protein, which retained the LMP1 cytoplasmic tail but has lost the constitutive activity of LMP1 and needs to be activated by the CD40 ligand. We show that LMP1 signaling can completely substitute CD40 signaling in B cells, leading to normal B-cell development, activation, and immune responses including class-switch recombination, germinal center formation, and somatic hypermutation. In addition, the LMP1-signaling domain has a unique property in that it can induce class-switch recombination to IgG1 independent of cytokines. Thus, our data indicate that LMP1 has evolved to imitate T-helper cell function allowing activation, proliferation, and differentiation of EBV-infected B cells independent of T cells.

scholarly journals Iκb Kinase α Is Essential for Mature B Cell Development and Function

2001 ◽  
Vol 193 (4) ◽  
pp. 417-426 ◽  
Author(s):  
Tsuneyasu Kaisho ◽  
Kiyoshi Takeda ◽  
Tohru Tsujimura ◽  
Taro Kawai ◽  
Fumiko Nomura ◽  
...  
Keyword(s):  
B Cells ◽  
B Cell ◽  
Fetal Liver ◽  
Cell Development ◽  
B Cell Development ◽  
Cytokine Signaling ◽  
Iκb Kinase ◽  
And Function

IκB kinase (IKK) α and β phosphorylate IκB proteins and activate the transcription factor, nuclear factor (NF)-κB. Although both are highly homologous kinases, gene targeting experiments revealed their differential roles in vivo. IKKα is involved in skin and limb morphogenesis, whereas IKKβ is essential for cytokine signaling. To elucidate in vivo roles of IKKα in hematopoietic cells, we have generated bone marrow chimeras by transferring control and IKKα-deficient fetal liver cells. The mature B cell population was decreased in IKKα−/− chimeras. IKKα−/− chimeras also exhibited a decrease of serum immunoglobulin basal level and impaired antigen-specific immune responses. Histologically, they also manifested marked disruption of germinal center formation and splenic microarchitectures that depend on mature B cells. IKKα−/− B cells not only showed impairment of survival and mitogenic responses in vitro, accompanied by decreased, although inducible, NF-κB activity, but also increased turnover rate in vivo. In addition, transgene expression of bcl-2 could only partially rescue impaired B cell development in IKKα−/− chimeras. Taken together, these results demonstrate that IKKα is critically involved in the prevention of cell death and functional development of mature B cells.

Enhancement of the Antigen-Presenting Cell Function of Mantle Cell Lymphomas (MCL) by Novel Molecularly Based Immunotherapeutic Strategies.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2315-2315
Author(s):  
Hongwei Wang ◽  
Fengdong Cheng ◽  
D. Noyes ◽  
K. Wright ◽  
S. Mohapatra ◽  
...  
Keyword(s):  
T Cells ◽  
B Cell ◽  
Histone Deacetylases ◽  
Cell Function ◽  
Antigen Presenting Cell ◽  
Ifn Gamma ◽  
Stat3 Signaling ◽  
Antigen Presenting ◽  
In Vitro Treatment

Abstract MCL is an aggressive and incurable B-cell malignancy with an intrinsic characteristic to relapse after an initial good response to treatment. Manipulation of the immune system to unleash its well-known specificity and long-lasting protective effect might provide a unique opportunity to induce more durable responses in MCL. In previous studies in an A20 B-cell lymphoma murine model we have demonstrated that augmentation of the antigen-presenting cell function of the malignant B-cell is required for elicitation of an effective anti-lymphoma immunity1. Inhibition of Stat3 signaling, a negative regulator of inflammatory responses, and modulation of histone deacetylases function were identified as two novel targets to augment the immunogenicity of the malignant B-cell. In this study we determined therefore whether manipulation of these intracellular pathways in murine and human MCL cells could result in priming of antigen-specific T-cells and/or restoration of the responsiveness of tolerant T-cells. First, in vitro treatment of FC-muMCL1 cells - cell line derived from a MCL tumor that arise following pristine injection into Em-cyclin D1 transgenic mice- with increasing concentrations of the Stat3 inhibitors, Cucurbitacin I (CuI) or CPA-7 resulted in an enhanced presentation of OVA-peptide to naive CD4+ T-cells specific for a MHC class II restricted epitope of Ovalbumin (OT-II cells). Indeed, these antigen-specific T-cells produce higher levels of IL-2 and IFN-gamma compared to anti-OVA T cells that encountered cognate antigen in FC-muMCL1 cells treated with LPS alone. Similarly, we found that culture of the human MCL cells JEKO or Z138 with allogeneic human peripheral blood mononuclear cells in the presence of increasing concentrations of the Stat3 inhibitors also resulted in increased IL-2 production by T-cells. In the next set of experiments, we determined whether treatment of FC-muMCL1 cells with the hydroxamic acid analogue pan-HDAC inhibitor LAQ824 could influence their antigen-presenting capabilities and their ability to activate T-cell responses. Unlike, MCL cells treated with LPS alone, FC-muMCL1 cells treated with LPS and LAQ824 effectively prime antigen-specific CD4+ T-cells as determined by their production of both IL-2 and IFN-gamma in response to cognate peptide. Furthermore, in vitro treatment of Z138 MCL cells with LAQ824 also led to enhanced IFN-gamma production by allogeneic human PBMCs. Taken together, our findings points to inhibition of Stat3 signaling and inhibition of histone deacetylases as appealing molecularly based immunotherapeutic strategies to augment the immunogenicity of MCL cells.

ABROGATION OF EPIDERMAL ANTIGEN-PRESENTING CELL FUNCTION BY ULTRAVIOLET RADIATION ADMINISTERED IN VIVO

1983 ◽  
Vol 36 (3) ◽  
pp. 304-309 ◽  
Author(s):  
MICHAEL F. GURISH ◽  
DAVID H. LYNCH ◽  
ROBERT YOWELL ◽  
RAYMOND A. DAYNES
Keyword(s):  
Ultraviolet Radiation ◽  
Cell Function ◽  
Antigen Presenting Cell ◽  
Antigen Presenting

scholarly journals Endogenous bcl-2 is not required for the development of Eμ-myc–induced B-cell lymphoma

Blood ◽  
2007 ◽  
Vol 109 (11) ◽  
pp. 4907-4913 ◽  
Author(s):  
Priscilla N. Kelly ◽  
Hamsa Puthalakath ◽  
Jerry M. Adams ◽  
Andreas Strasser
Keyword(s):  
B Cells ◽  
B Cell ◽  
Fetal Liver ◽  
Tumor Development ◽  
Early Death ◽  
B Cell Lymphoma ◽  
Lymphoid Cells ◽  
Tumor Dissemination ◽  
Transgenic Embryos

Abstract Although myc and bcl-2 synergize in tumor development, particularly lymphomagenesis, it is not known whether endogenous bcl-2 is required for myc-induced tumorigenesis. To investigate the role of endogenous Bcl-2 in myc-induced lymphomagenesis, we bypassed the early death of Bcl-2–deficient mice by reconstituting lethally irradiated wild-type (wt) mice with a hematopoietic system from fetal liver–derived stem cells of Eμ-myc/bcl-2−/− or control Eμ-myc transgenic embryos. In premalignant (healthy) recipients, loss of Bcl-2 caused a moderate decrease in pre-B and immature B cells, and a dramatic reduction of mature B lymphocytes expressing the Eμ-myc transgene. Furthermore, cultured preneoplastic Eμ-myc/bcl-2−/− mature B cells displayed accelerated apoptosis compared with Eμ-myc B cells. However, despite the striking reduction in B-cell numbers in vivo, ablation of endogenous Bcl-2 did not prevent or even delay development of Eμ-myc lymphoma. Moribund mice presented with similar degrees of splenomegaly, blood leukocyte numbers, and tumor dissemination at death. These findings demonstrate that the initiation, development, continued growth, and severity of Eμ-myc lymphoma do not depend upon endogenous Bcl-2, nor upon the total number of B lymphoid cells driven by the Eμ-myc transgene. These results have implications for the treatment of hematopoietic tumors, particularly those that are not caused by Bcl-2 overexpression.

Sign in / Sign up

Export Citation Format

Share Document